We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01113138
Recruitment Status : Completed
First Posted : April 29, 2010
Last Update Posted : January 13, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.

The aim of this part of the project is to study the pharmacokinetics of the following two magnesium supplements:

  • Mablet (dietary supplement)
  • Magnesium Sulfate (solution for infusion)

Condition or disease Intervention/treatment
Asthma Chronic Obstructive Pulmonary Disease Dietary Supplement: Mablet (Magnesium-supplement) Drug: Magnesium Sulfate

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetic Study of Mablet as Oral Supplement and Magnesium Sulfate as Infusion
Study Start Date : December 2012
Primary Completion Date : January 2014
Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
No Intervention: Baseline
Active Comparator: Mablet Dietary Supplement: Mablet (Magnesium-supplement)
Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
Other Name: Mablet
Active Comparator: Magnesium sulfate Drug: Magnesium Sulfate
Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
Other Name: Magnesiumsulfat 'SAD'

Outcome Measures

Primary Outcome Measures :
  1. Pharmacokinetic parameters [ Time Frame: Two years ]
    Clearance, half-life & absorption fraction

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers.

Exclusion Criteria:

  • Smokers,
  • Using pharmaceuticals/supplements,
  • Vegans/vegetarians,
  • Major changes in eating habits within one week prior to study start.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01113138

Research Dept. of Respiratory Medicine, Aarhus University Hospital
Aarhus C, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Gunnar Kjems APS
GCP-unit at Aarhus University Hospital, Aarhus, Denmark
Aarhus University Hospital
Principal Investigator: Ronald Dahl, Professor Dept. of Respiratory Medicine, Aarhus University Hospital
More Information


Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01113138     History of Changes
Other Study ID Numbers: 9727b
First Posted: April 29, 2010    Key Record Dates
Last Update Posted: January 13, 2014
Last Verified: January 2014

Keywords provided by University of Aarhus:
Absorption fraction

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Magnesium Sulfate
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents